Hemolytic-uremic syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Line 52: Line 52:
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
===Gender===
*HUS affects woman(59%) more than man(41%) .
*HUS affects woman(59%) more than man(41%) .<ref>{{Cite journal
| author = [[Deirdra R. Terrell]], [[Sara K. Vesely]], [[Johanna A. Kremer Hovinga]], [[Bernhard Lammle]] & [[James N. George]]
| title = Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes
| journal = [[American journal of hematology]]
| volume = 85
| issue = 11
| pages = 844–847
| year = 2010
| month = November
| doi = 10.1002/ajh.21833
| pmid = 20799358
}}</ref>
   
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.



Revision as of 20:25, 27 July 2018

Hemolytic-uremic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic-uremic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic-uremic syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic-uremic syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic-uremic syndrome epidemiology and demographics

CDC on Hemolytic-uremic syndrome epidemiology and demographics

Hemolytic-uremic syndrome epidemiology and demographics in the news

Blogs on Hemolytic-uremic syndrome epidemiology and demographics

Directions to Hospitals Treating Hemolytic-uremic syndrome

Risk calculators and risk factors for Hemolytic-uremic syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • The incidence of HUS is approximately 6 per 100,000 younger than 5 years old.[1]
  • In 2016, the incidence of HUS was estimated to be 2 cases per 100,000 individuals worldwide.[2]

Prevalence.

  • The incidence of HUS is approximately 6 per 100,000 younger than 5 years old.[1]
  • The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

Case-fatality rate/Mortality rate

  • In 2017, the incidence of hemolytic uremic syndrome (HUS) is approximately 10% .[3]
  • The case-fatality mortality rate of HUS is approximately 25%.[4]

Age

  • Patients of all age groups may develop hemolytic uremic syndrome (HUS).
  • The incidence of HUS increases with age; the median age at diagnosis is younger than 5 years.[2]
  • HUS commonly affects individuals younger 5 older than [number of years] years of age.[2]
  • [Chronic isease name] is usually first diagnosed among [age group].
  • [Acute disease name] commonly affects [age group].

Race

  • There is no racial predilection to [disease name].
  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • HUS affects woman(59%) more than man(41%) .[5]
  • [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References

  1. 1.0 1.1 Karpman D, Loos S, Tati R, Arvidsson I (February 2017). "Haemolytic uraemic syndrome". J. Intern. Med. 281 (2): 123–148. doi:10.1111/joim.12546. PMID 27723152.
  2. 2.0 2.1 2.2 Karpman, Diana; Loos, Sebastian; Tati, Ramesh; Arvidsson, Ida (2017). "Haemolytic uraemic syndrome". Journal of Internal Medicine. 281 (2): 123–148. doi:10.1111/joim.12546. ISSN 0954-6820.
  3. Gregory Hall, Shinichiro Kurosawa & Deborah J. Stearns-Kurosawa (2017). "Shiga Toxin Therapeutics: Beyond Neutralization". Toxins. 9 (9). doi:10.3390/toxins9090291. PMID 28925976. Unknown parameter |month= ignored (help)
  4. Gregory Hall, Shinichiro Kurosawa & Deborah J. Stearns-Kurosawa (2017). "Shiga Toxin Therapeutics: Beyond Neutralization". Toxins. 9 (9). doi:10.3390/toxins9090291. PMID 28925976. Unknown parameter |month= ignored (help)
  5. Deirdra R. Terrell, Sara K. Vesely, Johanna A. Kremer Hovinga, Bernhard Lammle & James N. George (2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". American journal of hematology. 85 (11): 844–847. doi:10.1002/ajh.21833. PMID 20799358. Unknown parameter |month= ignored (help)

Template:WH Template:WS